|
1
|
Pui CH, Relling MV and Downing JR: Acute
lymphoblastic leukemia. N Engl J Med. 350:1535–1548. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Tsai AG, Lu H, Raghavan SC, Muschen M,
Hsieh CL and Lieber MR: Human chromosomal translocations at CpG
sites and a theoretical basis for their lineage and stage
specificity. Cell. 135:1130–1142. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Papaemmanuil E, Rapado I, Li Y, Potter NE,
Wedge DC, Tubio J, Alexandrov LB, Van Loo P, Cooke SL, Marshall J,
et al: RAG-mediated recombination is the predominant driver of
oncogenic rearrangement in ETV6-RUNX1 acute lymphoblastic leukemia.
Nat Genet. 46:116–125. 2014. View
Article : Google Scholar : PubMed/NCBI
|
|
4
|
Swaminathan S, Klemm L, Park E,
Papaemmanuil E, Ford A, Kweon SM, Trageser D, Hasselfeld B, Henke
N, Mooster J, et al: Mechanisms of clonal evolution in childhood
acute lymphoblastic leukemia. Nat Immunol. 16:766–774. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Mandal M, Powers SE, Ochiai K,
Georgopoulos K, Kee BL, Singh H and Clark MR: Ras orchestrates exit
from the cell cycle and light-chain recombination during early B
cell development. Nat Immunol. 10:1110–1117. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Corcoran AE, Smart FM, Cowling RJ,
Crompton T, Owen MJ and Venkitaraman AR: The interleukin-7 receptor
alpha chain transmits distinct signals for proliferation and
differentiation during B lymphopoiesis. EMBO J. 15:1924–1932.
1996.PubMed/NCBI
|
|
7
|
Milne CD and Paige CJ: IL-7: A key
regulator of B lymphopoiesis. Semin Immunol. 18:20–30. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Touw I, Pouwels K, van Agthoven T, van
Gurp R, Budel L, Hoogerbrugge H, Delwel R, Goodwin R, Namen A and
Löwenberg B: Interleukin-7 is a growth factor of precursor B and T
acute lymphoblastic leukemia. Blood. 75:2097–2101. 1990.PubMed/NCBI
|
|
9
|
Nishii K, Katayama N, Miwa H, Shikami M,
Masuya M, Shiku H and Kita K: Survival of human leukaemic B-cell
precursors is supported by stromal cells and cytokines: Association
with the expression of bcl-2 protein. Br J Haematol. 105:701–710.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Barata JT, Keenan TD, Silva A, Nadler LM,
Boussiotis VA and Cardoso AA: Common gamma chain-signaling
cytokines promote proliferation of T-cell lymphoblastic leukemia.
Haematologica. 89:1459–1467. 2004.PubMed/NCBI
|
|
11
|
Silva A, Laranjeira AB, Martins LR,
Cardoso BA, Demengeot J, Yunes JA, Seddon B and Barata JT: IL-7
contributes to the progression of human T-cell acute lymphoblastic
leukemias. Cancer Res. 71:4780–4789. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Thiant S, Yakoub-Agha I, Magro L, Trauet
J, Coiteux V, Jouet JP, Dessaint JP and Labalette M: Plasma levels
of IL-7 and IL-15 in the first month after myeloablative BMT are
predictive biomarkers of both acute GVHD and relapse. Bone Marrow
Transplant. 45:1546–1552. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Brown VI, Fang J, Alcorn K, Barr R, Kim
JM, Wasserman R and Grupp SA: Rapamycin is active against
B-precursor leukemia in vitro and in vivo, an effect that is
modulated by IL-7-mediated signaling. Proc Natl Acad Sci USA.
100:15113–15118. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kosnopfel C, Sinnberg T and Schittek B:
Y-box binding protein 1-A prognostic marker and target in tumour
therapy. Eur J Cell Biol. 93:61–70. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Evdokimova V, Ovchinnikov LP and Sorensen
PH: Y-box binding protein 1: Providing a new angle on translational
regulation. Cell Cycle. 5:1143–1147. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Evdokimova V, Ruzanov P, Anglesio MS,
Sorokin AV, Ovchinnikov LP, Buckley J, Triche TJ, Sonenberg N and
Sorensen PH: Akt-mediated YB-1 phosphorylation activates
translation of silent mRNA species. Mol Cell Biol. 26:277–292.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Koike K, Uchiumi T, Ohga T, Toh S, Wada M,
Kohno K and Kuwano M: Nuclear translocation of the Y-box binding
protein by ultraviolet irradiation. FEBS Lett. 417:390–394. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Sutherland BW, Kucab J, Wu J, Lee C,
Cheang MC, Yorida E, Turbin D, Dedhar S, Nelson C, Pollak M, et al:
Akt phosphorylates the Y-box binding protein 1 at Ser102 located in
the cold shock domain and affects the anchorage-independent growth
of breast cancer cells. Oncogene. 24:4281–4292. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Shiota M, Takeuchi A, Song Y, Yokomizo A,
Kashiwagi E, Uchiumi T, Kuroiwa K, Tatsugami K, Fujimoto N, Oda Y
and Naito S: Y-box binding protein-1 promotes castration-resistant
prostate cancer growth via androgen receptor expression. Endocr
Relat Cancer. 18:505–517. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Stratford AL, Habibi G, Astanehe A, Jiang
H, Hu K, Park E, Shadeo A, Buys TP, Lam W, Pugh T, et al: Epidermal
growth factor receptor (EGFR) is transcriptionally induced by the
Y-box binding protein-1 (YB-1) and can be inhibited with Iressa in
basal-like breast cancer, providing a potential target for therapy.
Breast Cancer Res. 9:R612007. View
Article : Google Scholar : PubMed/NCBI
|
|
21
|
Davies AH and Dunn SE: YB-1 drives
preneoplastic progression: Insight into opportunities for cancer
prevention. Oncotarget. 2:401–406. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kim ER, Selyutina AA, Buldakov IA,
Evdokimova V, Ovchinnikov LP and Sorokin AV: The proteolytic YB-1
fragment interacts with DNA repair machinery and enhances survival
during DNA damaging stress. Cell Cycle. 12:3791–3803. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Bargou RC, Jürchott K, Wagener C, Bergmann
S, Metzner S, Bommert K, Mapara MY, Winzer KJ, Dietel M, Dörken B
and Royer HD: Nuclear localization and increased levels of
transcription factor YB-1 in primary human breast cancers are
associated with intrinsic MDR1 gene expression. Nat Med. 3:447–450.
1997. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Chatterjee M, Rancso C, Stühmer T,
Eckstein N, Andrulis M, Gerecke C, Lorentz H, Royer HD and Bargou
RC: The Y-box binding protein YB-1 is associated with progressive
disease and mediates survival and drug resistance in multiple
myeloma. Blood. 111:3714–3722. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Lasham A, Print CG, Woolley AG, Dunn SE
and Braithwaite AW: YB-1: Oncoprotein, prognostic marker and
therapeutic target? Biochem J. 449:11–23. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Szczuraszek K, Halon A, Materna V, Mazur
G, Wrobel T, Kuliczkowski K, Donizy P, Holm PS, Lage H and Surowiak
P: Elevated YB-1 expression is a new unfavorable prognostic factor
in non-Hodgkin's lymphomas. Anticancer Res. 31:2963–2970.
2011.PubMed/NCBI
|
|
27
|
Shen H, Xu W, Luo W, Zhou L, Yong W, Chen
F, Wu C, Chen Q and Han X: Upregulation of mdr1 gene is related to
activation of the MAPK/ERK signal transduction pathway and YB-1
nuclear translocation in B-cell lymphoma. Exp Hematol. 39:558–569.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Hanzawa K, Momose S, Higashi M, Tokuhira
M, Watanabe R, Kajino K, Hino O, Itoyama S, Kizaki M and Tamaru J:
Y-box binding protein-1 expression in diffuse large B-cell
lymphoma: An impact on prognosis in the rituximab era. Leuk
Lymphoma. 51:2054–2062. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Castellana B, Aasen T, Moreno-Bueno G,
Dunn SE and Ramón y Cajal S: Interplay between YB-1 and IL-6
promotes the metastatic phenotype in breast cancer cells.
Oncotarget. 6:38239–38256. 2015.PubMed/NCBI
|
|
30
|
Barrett DM, Seif AE, Carpenito C, Teachey
DT, Fish JD, June CH, Grupp SA and Reid GS: Noninvasive
bioluminescent imaging of primary patient acute lymphoblastic
leukemia: A strategy for preclinical modeling. Blood.
118:e112–e117. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Guay D, Evoy AA, Paquet E, Garand C,
Bachvarova M, Bachvarov D and Lebel M: The strand separation and
nuclease activities associated with YB-1 are dispensable for
cisplatin resistance but overexpression of YB-1 in MCF7 and
MDA-MB-231 breast tumor cells generates several chemoresistance
signatures. Int J Biochem Cell Biol. 40:2492–2507. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Brown VI, Fang J, Alcorn K, Barr R, Kim
JM, Wasserman R and Grupp SA: Rapamycin is active against
B-precursor leukemia in vitro and in vivo, an effect that is
modulated by IL-7-mediated signaling. Proc Natl Acad Sci USA.
100:15113–15118. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Fujii T, Kawahara A, Basaki Y, Hattori S,
Nakashima K, Nakano K, Shirouzu K, Kohno K, Yanagawa T, Yamana H,
et al: Expression of HER2 and estrogen receptor alpha depends upon
nuclear localization of Y-box binding protein-1 in human breast
cancers. Cancer Res. 68:1504–1512. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Basaki Y, Hosoi F, Oda Y, Fotovati A,
Maruyama Y, Oie S, Ono M, Izumi H, Kohno K, Sakai K, et al:
Akt-dependent nuclear localization of Y-box-binding protein 1 in
acquisition of malignant characteristics by human ovarian cancer
cells. Oncogene. 26:2736–2746. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Stratford AL, Fry CJ, Desilets C, Davies
AH, Cho YY, Li Y, Dong Z, Berquin IM, Roux PP and Dunn SE: Y-box
binding protein-1 serine 102 is a downstream target of p90
ribosomal S6 kinase in basal-like breast cancer cells. Breast
Cancer Res. 10:R992008. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
van der Plas DC, Smiers F, Pouwels K,
Hoefsloot LH, Löwenberg B and Touw IP: Interleukin-7 signaling in
human B cell precursor acute lymphoblastic leukemia cells and
murine BAF3 cells involves activation of STAT1 and STAT5 mediated
via the interleukin-7 receptor alpha chain. Leukemia. 10:1317–1325.
1996.PubMed/NCBI
|
|
38
|
Venkitaraman AR and Cowling RJ:
Interleukin-7 induces the association of phosphatidylinositol
3-kinase with the alpha chain of the interleukin-7 receptor. Eur J
Immunol. 24:2168–2174. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Steelman LS, Abrams SL, Whelan J, Bertrand
FE, Ludwig DE, Bäsecke J, Libra M, Stivala F, Milella M, Tafuri A,
et al: Contributions of the Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and
Jak/STAT pathways to leukemia. Leukemia. 22:686–707. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Fleming HE and Paige CJ: Pre-B cell
receptor signaling mediates selective response to IL-7 at the Pro-B
to Pre-B cell transition via an ERK/MAP kinase-dependent pathway.
Immunity. 15:521–531. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Lyabin DN, Eliseeva IA and Ovchinnikov LP:
YB-1 synthesis is regulated by mTOR signaling pathway. PLoS One.
7:e525272012. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Brown VI, Hulitt J, Fish J, Sheen C, Bruno
M, Xu Q, Carroll M, Fang J, Teachey D and Grupp SA: Thymic
stromal-derived lymphopoietin induces proliferation of pre-B
leukemia and antagonizes mTOR inhibitors, suggesting a role for
interleukin-7Ralpha signaling. Cancer Res. 67:9963–9970. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Shochat C, Tal N, Bandapalli OR, Palmi C,
Ganmore I, te Kronnie G, Cario G, Cazzaniga G, Kulozik AE, Stanulla
M, et al: Gain-of-function mutations in interleukin-7 receptor-α
(IL7R) in childhood acute lymphoblastic leukemias. J Exp Med.
208:901–908. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Zenatti PP, Ribeiro D, Li W, Zuurbier L,
Silva MC, Paganin M, Tritapoe J, Hixon JA, Silveira AB, Cardoso BA,
et al: Oncogenic IL7R gain-of-function mutations in childhood
T-cell acute lymphoblastic leukemia. Nat Genet. 43:932–939. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Somasekharan SP, Stoynov N, Rotblat B,
Leprivier G, Galpin JD, Ahern CA, Foster LJ and Sorensen PH:
Identification and quantification of newly synthesized proteins
translationally regulated by YB-1 using a novel Click-SILAC
approach. J Proteomics. 77:e1–e10. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Troiano A, Lomoriello IS, di Martino O,
Fusco S, Pollice A, Vivo M, La Mantia G and Calabrò V: Y-box
binding Protein-1 Is part of a complex molecular network linking
ΔNp63α to the PI3K/akt pathway in cutaneous squamous cell
carcinoma. J Cell Physiol. 230:2067–2074. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Silva A, Cebola I, Santos CI, Antunes F
and Barata JT: Intracellular reactive oxygen species are essential
for PI3K/Akt/mTOR-dependent IL-7-mediated viability of T-cell acute
lymphoblastic leukemia cells. Leukemia. 25:960–967. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Winston LA and Hunter T: JAK2, Ras, and
Raf are required for activation of extracellular signal-regulated
kinase/mitogen-activated protein kinase by growth hormone. J Biol
Chem. 270:30837–30840. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Johnson SE, Shah N, Panoskaltsis-Mortari A
and LeBien TW: Murine and human IL-7 activate STAT5 and induce
proliferation of normal human pro-B cells. J Immunol.
175:7325–7331. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
To K, Fotovati A, Reipas KM, Law JH, Hu K,
Wang J, Astanehe A, Davies AH, Lee L, Stratford AL, et al: Y-box
binding protein-1 induces the expression of CD44 and CD49f leading
to enhanced self-renewal, mammosphere growth, and drug resistance.
Cancer Res. 70:2840–2851. 2010. View Article : Google Scholar : PubMed/NCBI
|
